Company Legal Name
Latest Valuation
Founded Year
Headquarters
Freenome Holdings, Inc. develops advanced blood tests that analyze multiomic biomarkers to detect early-stage cancer signals, addressing the critical need for non-invasive cancer screening solutions. Founded in 2014 and headquartered in South San Francisco, the company leverages artificial intelligence and machine learning to identify patterns in circulating tumor DNA, proteins, and other biological markers present in blood samples. Freenome's platform aims to transform cancer detection by enabling earlier intervention when treatments are most effective. The company continues advancing its proprietary technology through clinical trials and partnerships, positioning itself at the forefront of liquid biopsy innovation in oncology diagnostics.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
